DE69618578D1 - Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata - Google Patents

Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata

Info

Publication number
DE69618578D1
DE69618578D1 DE69618578T DE69618578T DE69618578D1 DE 69618578 D1 DE69618578 D1 DE 69618578D1 DE 69618578 T DE69618578 T DE 69618578T DE 69618578 T DE69618578 T DE 69618578T DE 69618578 D1 DE69618578 D1 DE 69618578D1
Authority
DE
Germany
Prior art keywords
hypertrophy
gonadotropin
prostate
treat
started
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69618578T
Other languages
English (en)
Other versions
DE69618578T2 (de
Inventor
John Mcmichael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Milkhaus Laboratory Inc
Original Assignee
Milkhaus Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Laboratory Inc filed Critical Milkhaus Laboratory Inc
Publication of DE69618578D1 publication Critical patent/DE69618578D1/de
Application granted granted Critical
Publication of DE69618578T2 publication Critical patent/DE69618578T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
DE69618578T 1996-01-30 1996-10-30 Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata Expired - Lifetime DE69618578T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/593,501 US5610136A (en) 1996-01-30 1996-01-30 Method for treatment of benign prostatic hypertrophy
PCT/US1996/017421 WO1997027869A1 (en) 1996-01-30 1996-10-30 Method for treatment of benign prostatic hypertrophy

Publications (2)

Publication Number Publication Date
DE69618578D1 true DE69618578D1 (de) 2002-02-21
DE69618578T2 DE69618578T2 (de) 2003-01-23

Family

ID=24374964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69618578T Expired - Lifetime DE69618578T2 (de) 1996-01-30 1996-10-30 Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata

Country Status (8)

Country Link
US (1) US5610136A (de)
EP (1) EP0817645B1 (de)
JP (1) JP2971950B2 (de)
AT (1) ATE211921T1 (de)
AU (1) AU705524B2 (de)
CA (1) CA2216810C (de)
DE (1) DE69618578T2 (de)
WO (1) WO1997027869A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
US7101847B2 (en) * 2002-10-11 2006-09-05 Milkhaus Laboratory, Inc. Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
US7605122B2 (en) * 2005-07-29 2009-10-20 Millennium Medical Spa Human chorionic gonadotropin (hCG) formulations for facilitating weight loss and body contouring
US20080139457A1 (en) * 2005-09-16 2008-06-12 Virginia Commonwealth University Therapeutic compositions comprising chorionic gonadotropins and HMG CoA reductase inhibitors
US9707403B2 (en) 2007-12-12 2017-07-18 Neuro Code Tech Holdings, Llc Rapid destruction of malignant tumors by excitotoxicity and osmotic-shock medical tactics
US8656930B2 (en) * 2008-01-10 2014-02-25 Neuro-Code Tech Holdings, LLC Method and system for processing cancer cell electrical signals for medical therapy
AU2009257948A1 (en) 2008-04-17 2009-12-17 Neuro-Code Technologies, Llc System and method to elicit apoptosis in malignant tumor cells for medical treatment
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US11154238B2 (en) 2015-08-07 2021-10-26 Electroceuticals, Llc Systems, methods and apparatuses for providing bioelectronic neurocode-based therapies to mammals

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691006A (en) * 1983-03-04 1987-09-01 Ohio State University Antigenic modification of polypeptides
US4384995A (en) * 1980-01-16 1983-05-24 The Ohio State University Antigenic modification of polypeptides
US4526716A (en) * 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4201770A (en) * 1973-05-07 1980-05-06 The Ohio State University Antigenic modification of polypeptides
US4302386A (en) * 1978-08-25 1981-11-24 The Ohio State University Antigenic modification of polypeptides
US4002738A (en) * 1975-05-30 1977-01-11 Abbott Laboratories Treatment of specified neoplasias
US4116776A (en) * 1976-04-19 1978-09-26 International Radioimmune Systems, Inc. Diagnostic blood test and kit for detecting human chorionic gonadotropin
US4144031A (en) * 1976-04-19 1979-03-13 International Radioimmune Systems, Inc. Cell test for detecting human chorionic gonadotropin
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4321260A (en) * 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia
US4692332A (en) * 1985-01-18 1987-09-08 Mcmichael John Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms

Also Published As

Publication number Publication date
EP0817645A4 (de) 2000-11-29
AU7527896A (en) 1997-08-22
EP0817645A1 (de) 1998-01-14
US5610136A (en) 1997-03-11
WO1997027869A1 (en) 1997-08-07
AU705524B2 (en) 1999-05-27
EP0817645B1 (de) 2002-01-16
JPH10507468A (ja) 1998-07-21
ATE211921T1 (de) 2002-02-15
JP2971950B2 (ja) 1999-11-08
CA2216810C (en) 2005-04-26
DE69618578T2 (de) 2003-01-23
CA2216810A1 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
DE69618578D1 (de) Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE242238T1 (de) Chinolin- und chinazolin-verbindungen von therapeutischem nutzen, insbesondere zur behandlung von gutartiger prostatahyperplasie
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
NO976078D0 (no) Fremgangsmåte for å behandle godartet prostatisk hyperplasi med varmeterapi
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE370743T1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
ATE222489T1 (de) Thyroxin-analoga ohne bedeutende hormonale wirkung zur behandlung von bösartigen tumoren
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
EP0646007A4 (de)
NO994330L (no) Metode for behandling av en tumor
ATE253061T1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE300295T1 (de) Verwendung von baclofen zur behandlung von alkoholismus
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
DE60313603D1 (de) Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
NO20004141D0 (no) Nye substituerte pyridinoarylpiperaziner er anvendelige ved behandling av benign prostatahyperplasi
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
EA199800859A1 (ru) Способ лечения при ядовитых укусах и ужалениях
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted